Ardelyx (NASDAQ:ARDX) Insider James Parker Brady Sells 15,136 Shares

Ardelyx, Inc. (NASDAQ:ARDX) insider James Parker Brady sold 15,136 shares of Ardelyx stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $58,424.96. Following the transaction, the insider owned 245,930 shares in the company, valued at approximately $949,289.80. This trade represents a 5.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ardelyx Stock Up 1.1%

ARDX opened at $3.78 on Wednesday. The company has a debt-to-equity ratio of 1.69, a quick ratio of 3.15 and a current ratio of 3.34. The company has a market capitalization of $941.94 million, a PE ratio of -17.18 and a beta of 0.70. The stock’s fifty day moving average is $4.97 and its 200-day moving average is $5.75. Ardelyx, Inc. has a one year low of $3.72 and a one year high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The company’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.08) EPS. On average, equities analysts predict that Ardelyx, Inc. will post -0.2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARDX. California State Teachers Retirement System increased its position in shares of Ardelyx by 397.4% in the second quarter. California State Teachers Retirement System now owns 1,507,739 shares of the biopharmaceutical company’s stock worth $7,689,000 after acquiring an additional 1,204,602 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Ardelyx by 8.2% in the 2nd quarter. Headlands Technologies LLC now owns 240,796 shares of the biopharmaceutical company’s stock valued at $1,228,000 after acquiring an additional 18,264 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Ardelyx by 10.4% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 486,412 shares of the biopharmaceutical company’s stock worth $2,481,000 after purchasing an additional 45,738 shares during the period. Hsbc Holdings PLC boosted its stake in Ardelyx by 7.0% in the 2nd quarter. Hsbc Holdings PLC now owns 100,550 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 6,619 shares during the period. Finally, Bank of America Corp DE purchased a new position in Ardelyx during the 2nd quarter worth approximately $11,034,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Analyst Ratings Changes

Several brokerages have recently issued reports on ARDX. Weiss Ratings cut shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 29th. TD Cowen reduced their target price on shares of Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 7th. Zacks Research lowered shares of Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Piper Sandler dropped their price target on Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Monday, August 17th. Finally, Wedbush restated an “outperform” rating and issued a $9.00 target price on shares of Ardelyx in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Ardelyx has a consensus rating of “Moderate Buy” and a consensus target price of $13.90.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio?renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.